VIVOS THERAPEUTICS INC

Company Overview

Vivos Therapeutics (VVOS) is a revenue-stage medical technology company that commercializes The Vivos Method — a non-surgical, device-plus-services treatment system for dentofacial abnormalities and obstructive sleep apnea (OSA). Core revenues come from FDA-cleared oral appliances (DNA/mRNA/mmRNA), home sleep testing (VivoScore/HST leasing), software/billing services, training and appliance sales; 2024 consolidated revenue was $15.0M with ~60% gross margin and ~58,000 treated patients reported historically. In 2024–2025 the company pivoted from a dentist-VIP subscription model toward alliance/profit-share deals and selective acquisitions (closed The Sleep Center of Nevada in June 2025), opened partial in-house fabrication to improve margins, and faces material liquidity and execution risks tied to scaling alliances, reimbursement, and clinical evidence development.

Executive Compensation Practices

Given Vivos’s continued operating losses (2024 operating loss ~$11.2M; Q2 2025 widening operating loss) and constrained liquidity, executive pay is likely to be equity-heavy and oriented toward non-cash incentives (stock awards, options, warrants) to conserve cash while aligning management to growth and retention. Short- and long-term incentives are likely tied to commercial metrics critical to the pivot: appliance sales/ASP, HST volume and conversion rates, successful alliance rollouts or acquisition integrations (e.g., SCN), reimbursement milestones (AMA CPT/Medicare positioning) and clinical trial outcomes that expand indications. Cost-control and liquidity targets (reducing G&A, meeting Nasdaq requirements, successful financing closings) are also probable performance levers for cash bonuses or vesting; warrant accounting and past material warrant expense indicate executives may receive or manage complex derivative instruments as part of compensation.

Insider Trading Considerations

Insider trading patterns at Vivos will be sensitive to discrete, value-driving events: FDA/clinical trial updates (including pediatric indications and the paused Stanford trial), reimbursement/CPT developments, alliance or acquisition announcements (SCN acquisition and future JV rollouts), and financing activities (PIPE, secured notes, equity issuances) that often cause insiders to acquire or sell shares or warrants. Expect frequent Form 4 activity tied to option exercises, grant vesting, or participation in financings; watch for sales clustered around financing closings or immediate post-exercise dispositions, which may reflect liquidity needs rather than positive signals. Given healthcare regulatory exposure (anti-kickback, corporate practice of medicine, HIPAA) and material nonpublic information tied to patient-provider contracts and clinical results, look for blackout periods and use of 10b5-1 plans; traders should monitor rapid insider purchases (potential positive signal) versus financing-related sales (potential dilution/need-for-cash signal).